SYT: A Potential Drug Target for Neurological Disorders (P46534)

Target Name: Synaptotagmin

NCBI ID: P46534

Synaptotagmin

Other Name(s): SYT

SYT: A Potential Drug Target for Neurological Disorders

Synaptotagmin (SYT) is a protein that is expressed in the rat central nervous system and is involved in the regulation of synaptic strength and neurotransmitter release. It is a member of the neurotrophic factor family and is thought to play a role in the development and maintenance of synaptic plasticity.

Recent studies have suggested that SYT may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because SYT has been shown to be involved in the pathophysiology of these conditions and may be a useful target for new treatments.

One of the potential benefits of targeting SYT is its potential to modulate neurotransmitter release and improve synaptic function. This is because SYT is involved in the regulation of neurotransmitter release from dopamine-producing neurons, which are important for various functions in the brain, including mood regulation and movement.

In addition, SYT has also been shown to play a role in the regulation of synaptic strength, which is the ability of synapses to transmit signals. This is important for the development and maintenance of synaptic plasticity, which is the ability of the brain to learn and adapt over time.

SYT has also been shown to be involved in the regulation of axon growth and differentiation, which is important for the development and maintenance of neural circuits. This is important for the development and maintenance of neural circuits, which are responsible for transmitting signals throughout the brain.

In conclusion, SYT is a protein that is involved in the regulation of synaptic strength and neurotransmitter release, and has been shown to play a role in the development and maintenance of synaptic plasticity. As a result, targeting SYT may be a promising approach for the development of new treatments for various neurological and psychiatric disorders.

Protein Name: Synaptotagmin (nonspecified Subtype)

The "Synaptotagmin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Synaptotagmin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets